CTS Corporation's CEO, Kieran O'Sullivan, expressed positive sentiments about Dodrill's appointment, highlighting her extensive experience in the medical end market and her background in leading global businesses as valuable assets to the company's growth and diversification efforts.

CTS's high P/E ratio is likely due to investors' expectations of strong future growth and market outperformance. Shareholders appear comfortable with the P/E ratio and confident in future earnings, with a low likelihood of a significant share price drop soon.

CTS' consistent EPS growth and stable revenues, along with the significant investment from insiders signal strong confidence in the company's business strategy. It may be a good stock to follow for investors due to its fast growth and confident insiders.

CTS's ability to maintain good return rates on capital and reinvest at these rates, despite increased investment, hints at its long-term investment potential. The flat ROCE trend could offer substantial rewards to shareholders over time.